List view / Grid view
21 December 2015 | By Victoria White
MSD has announced results from the Phase 2/3 KEYNOTE-010 study of Keytruda (pembrolizumab) in patients with previously treated non-small cell lung cancer (NSCLC)...
10 November 2015 | By Victoria White
The SMC also announced positive recommendations for Roche’s Avastin (bevacizumab) and Daiichi Sankyo’s Lixiana (edoxaban)...
9 October 2015 | By Victoria White
This new recommendation for Keytruda is for treating advanced melanoma that has not been previously treated with ipilimumab...
7 October 2015 | By
Pembrolizumab was the first drug to be approved through the Medicines and Healthcare Products Regulatory Agency’s Early Access to Medicine Scheme (EAMS)...
7 September 2015 | By Victoria White
NICE has recommended that pembrolizumab is made available on the NHS as a treatment for some patients with advanced melanoma which is either unresectable or metastatic...
30 June 2015 | By Victoria White
MSD recently announced the primary results of the TECOS trial, a placebo-controlled study of the cardiovascular safety of MSD’s DPP-4 inhibitor, sitagliptin...
26 June 2015 | By Victoria White
The EC has approved Simponi (golimumab) for the treatment of adult patients with severe, active non-radiographic axial spondyloarthritis (nr-axial SpA)...
17 June 2015 | By Victoria White
GARDASIL 9 is approved in the EU for active immunisation against premalignant lesions and cancers affecting the cervix, vulva, vagina or anus...
10 June 2015 | By Victoria White
MSD has announced additional data from a subanalysis of the GO-AHEAD study on the effect of Simponi in treating patients with nr-axial SpA...
15 December 2014 | By MSD
NICE says ‘yes’ to REMICADE® (infliximab), HUMIRA® (adalimumab) and SIMPONI® (golimumab) for adult patients with moderately to severely active ulcerative colitis...
19 November 2014 | By MSD
Application for approval of new indication for golimumab has been filed with the European Medicines Agency...
13 October 2014 | By MSD
NICE draft guidance says no to biologic treatments for patients with moderate-to-severe ulcerative colitis – potentially missing the opportunity to provide an alternative...
21 February 2013 | By Michael J. Miller, President, Microbiology Consultants, LLC, Silvia Fragoeiro, Ananthi Ramachandran and Paul van Empel MSD Animal Health
This is the first paper in our continuing series on Rapid Microbiological Methods (RMM) that will appear in European Pharmaceutical Review during 2013. Flow cytometry represents one of a variety of viability-based RMM technologies that are currently available to the pharmaceutical industry. In flow cytometry, individual particles are counted as…
6 December 2011 | By MSD
Data presented at the IDF 21st World Diabetes Congress...
11 April 2011 | By Merck
After a pre-specified interim analysis the DMC has recommended suspension of enrollment...
